The biotech landscape is shifting as China leverages its regulatory efficiency and cost advantages in clinical trial execution. With streamlined approval processes and lower operational expenses, Chinese biotech companies are accelerating drug development cycles, prompting US policymakers and industry leaders to reassess competitive strategies. This emerging disparity in trial capabilities raises critical questions about innovation leadership, regulatory frameworks, and future biotechnology dominance in the global market.

Summary auto-generated by AI from the original publisher's content. Editorial standards.